AbbVie Inc.
About AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $61.2B
- Net income
- $4.2B
- Total assets
- $134.0B
- Market cap
- $401.5B
- Gross margin
- 70.2%
- Operating margin
- 24.6%
- Net margin
- 6.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $61.2B
- Cost of revenue
- $18.2B
- Gross profit
- $43.0B
- Operating expenses
- $27.9B
- Operating income
- $15.1B
- Income tax
- $2.4B
- Net income
- $4.2B
- EPS (basic)
- $2.37
- EPS (diluted)
- $2.36
Balance sheet
- Total assets
- $134.0B
- Current assets
- $29.1B
- Total liabilities
- $137.2B
- Current liabilities
- $43.3B
- Shareholders’ equity
- -$3.2B
Cash flow
- Operating cash flow
- $19.0B
- Investing cash flow
- -$6.6B
- Financing cash flow
- -$12.7B
- Net cash flow
- -$295.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $401.5B
- P/E ratio
- 94.5
- EPS (diluted)
- $2.36
- Dividend yield
- 3.1%
- Shares outstanding
- 1.8B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 10, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $4.2B in FY2025.
- Revenue grew 34% from FY2020 to FY2025.
- Gross margin of 70.2%, net margin 6.9%.
- Trading 9% below its 52-week high.
- Pays a dividend yielding about 3.1% annually.
- Valued at a price-to-earnings (P/E) ratio of 94.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AbbVie Inc..
Write a review
News about AbbVie Inc.
News & sentiment via Polygon.io
